Furthermore, we observed that lower expression levels of YBX3 were associated with improved clinical outcomes for ICB therapy (PDL1 or PD1) in bladder cancer and glioblastomas and consequently longer survival times (Supplementary Figure S1–5B, upper row). The gene discussed is YBX3; the disease is glioblastoma.